Innovent Biopharmaceutical Transformation
Sintilimab in 2021: The Only PD-1 Inhibitor with Positive Phase 3 Data in
the First Line Treatment of 5 Major Types of Cancer
Overall survival (%)
100
75
75
50
25
1L sq NSCLC
2021.06 SNDA Approval
هی
1L ESCC
2021.06 ORIENT-15 met endpoints
2021.09 SNDA Accepted
1L GC
EGFRM nsqNSCLC
2021.11 ORIENT-31 met endpoints
2021.12 SNDA Accepted
1L nsqNSCLC
2021.02 SNDA Approval
1L HCC
2021.06 SNDA Approval
2021.08 ORIENT-16 met endpoints
2021.10 SNDA Accepted
A successful year with 3 sNDA approvals, 3 Ph3 data readouts and 3 new sNDA accepted
EGFRm nsqNSCLC: ORIENT-31
1L ESCC: ORIENT-15
Improved mOS: 16.7 mos V.S. 12.5 mos
(HR [95% CI]=0.628, p<0.0001)
WIIHIII
Sinti + Chemo
1L GC/GEJ: ORIENT-16
1.0-
Improved mOS: 15.2 mos V.S. 12.3 mos
(HR[95% CI]=0.766, p=0.0090)
0.8-
Overall survival (%)
70
0.2-
0.4-
0.6-
Chemo
0
T
T
0
3
6
9
12
15
18
21
24
27
0
3
6
9
12
15
18
21
Months
Months
Innovent
Confidential
Copyright©2022 Innovent
Sinti + Chemo
Chemo
T
25
24
27
22
30
Progression free survival (%)
100-
80-
60
40-
20
20
Improved mPFS: 6.9 mos V.S. 4.3 mos
(HR [95% CI]=0.464, p<0.0001)
CO
13
Months
0
Sinti+ Bevaci Chemo
Chemo
12
15
8View entire presentation